Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedMar 06, 2026
DataAggregated Company Financials
Companies7
  • 7D-3.0%
  • 3M-2.9%
  • 1Y-10.4%
  • YTD-2.7%

Over the last 7 days, the Life Sciences industry has dropped 3.0%, driven by declines from every company within the industry. However, the industry is down 10% over the past year. Looking forward, earnings are forecast to grow by 18% annually.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 06 Mar 2026CHF 47.7bCHF 10.1bCHF 1.3b29.3x37x4.7x
Sun, 01 Feb 2026CHF 50.3bCHF 10.1bCHF 1.3b33.2x39.5x5x
Tue, 30 Dec 2025CHF 49.2bCHF 10.6bCHF 1.1b29.8x44.8x4.6x
Thu, 27 Nov 2025CHF 48.7bCHF 10.6bCHF 1.1b28.2x44.3x4.6x
Sat, 25 Oct 2025CHF 53.2bCHF 10.6bCHF 1.1b31.4x48.4x5x
Mon, 22 Sep 2025CHF 51.0bCHF 10.6bCHF 1.1b34.3x46.3x4.8x
Wed, 20 Aug 2025CHF 53.3bCHF 10.7bCHF 1.1b36.3x47.2x5x
Fri, 18 Jul 2025CHF 53.1bCHF 10.1bCHF 1.0b33.3x51.1x5.3x
Sun, 15 Jun 2025CHF 52.9bCHF 10.1bCHF 1.0b32.5x51x5.2x
Tue, 13 May 2025CHF 53.4bCHF 10.1bCHF 1.0b32.6x51.4x5.3x
Thu, 10 Apr 2025CHF 46.2bCHF 10.1bCHF 1.0b27x45.1x4.6x
Sat, 08 Mar 2025CHF 53.9bCHF 10.1bCHF 1.0b30.1x51.6x5.3x
Mon, 03 Feb 2025CHF 56.6bCHF 10.1bCHF 1.0b36.4x56.2x5.6x
Wed, 01 Jan 2025CHF 52.7bCHF 10.2bCHF 943.4m35.5x55.8x5.2x
Fri, 29 Nov 2024CHF 52.9bCHF 10.2bCHF 943.6m40.8x56x5.2x
Sun, 27 Oct 2024CHF 56.0bCHF 10.2bCHF 943.5m42x59.4x5.5x
Tue, 24 Sep 2024CHF 55.1bCHF 10.2bCHF 943.1m42.7x58.5x5.4x
Thu, 22 Aug 2024CHF 57.3bCHF 10.2bCHF 920.6m46.5x62.3x5.6x
Sat, 20 Jul 2024CHF 54.0bCHF 10.3bCHF 1.0b46.8x53.9x5.3x
Mon, 17 Jun 2024CHF 51.8bCHF 10.3bCHF 1.0b44.3x51.7x5x
Wed, 15 May 2024CHF 54.1bCHF 10.3bCHF 1.0b44.5x54.1x5.3x
Fri, 12 Apr 2024CHF 56.5bCHF 10.3bCHF 1.0b44.8x56.3x5.5x
Sun, 10 Mar 2024CHF 51.9bCHF 10.2bCHF 995.4m48.1x52.1x5.1x
Tue, 06 Feb 2024CHF 47.7bCHF 10.2bCHF 1.0b41.3x46.8x4.7x
Thu, 04 Jan 2024CHF 41.1bCHF 9.8bCHF 1.5b31.2x27.5x4.2x
Sat, 02 Dec 2023CHF 39.6bCHF 9.8bCHF 1.5b29.4x26.5x4.1x
Mon, 30 Oct 2023CHF 36.6bCHF 9.8bCHF 1.5b25.6x24.5x3.7x
Wed, 27 Sep 2023CHF 46.8bCHF 9.8bCHF 1.5b32.1x31.4x4.8x
Fri, 25 Aug 2023CHF 52.2bCHF 9.8bCHF 1.5b36x35x5.3x
Sun, 23 Jul 2023CHF 52.2bCHF 9.8bCHF 1.5b36.1x33.7x5.3x
Tue, 20 Jun 2023CHF 57.2bCHF 9.7bCHF 1.6b36x35x5.9x
Thu, 18 May 2023CHF 59.4bCHF 9.7bCHF 1.6b38.1x36.4x6.1x
Sat, 15 Apr 2023CHF 61.4bCHF 9.7bCHF 1.7b42.3x36.8x6.3x
Mon, 13 Mar 2023CHF 55.9bCHF 9.6bCHF 1.7b32.6x33.6x5.8x
Price to Earnings Ratio

33.6x


Total Market Cap: CHF 55.9bTotal Earnings: CHF 1.7bTotal Revenue: CHF 9.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 45.9x202420252026
Current Industry PE
  • Investors are pessimistic on the Swiss Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 37.0x which is lower than its 3-year average PE of 45.9x.
  • The industry is trading close to its 3-year average PS ratio of 5.2x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 8.1% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market-3.92%
Healthcare-2.87%
Life Sciences-2.99%
Clinical Research and Equipment-2.99%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
No data available

Latest News

PPGN
CHF 23.75
PolyPeptide Group
7D
-7.6%
1Y
21.4%
TECN
CHF 127.80
Tecan Group
7D
-6.2%
1Y
-32.0%

TECN: Mixed Research Views And Investor Day Outlook Shape Future Expectations

Analysts have trimmed their price target for Tecan Group to CHF 137.00 from CHF 165.20, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E. Recent research also includes both a Morgan Stanley target cut and target and rating adjustments from other firms.
BANB
CHF 55.60
Bachem Holding
7D
-6.4%
1Y
-1.0%

BANB: Future Execution On Pipeline Plans Will Support Higher Market Confidence

The updated analyst price target for Bachem Holding suggests a modest upward revision to fair value to CHF 78.66, with analysts citing slightly adjusted assumptions for the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a signal that their assumptions for Bachem Holding’s future earnings and cash flows now support a fair value above the prior level, even after revisiting discount rate and P/E inputs.
SKAN
CHF 49.40
SKAN Group
7D
-5.5%
1Y
-33.0%

SKAN: Stable Assumptions And Consistent Future P/E Will Support Upside Potential

Analysts have kept their CHF 70.33 price target on SKAN Group broadly unchanged, reflecting only marginal tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, rather than a shift in their overall view. Valuation Changes Fair Value: CHF 70.33 remains unchanged, indicating no adjustment to the headline valuation estimate.
SFZN
CHF 79.10
Siegfried Holding
7D
-7.7%
1Y
-14.3%

SFZN: Margin Resilience And Efficiency Focus Will Support Future Rerating

Analysts have trimmed their price target for Siegfried Holding to CHF 136, reflecting slightly softer revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple, partly offset by expectations for a higher profit margin. Analyst Commentary Recent research has become more cautious on Siegfried Holding, with at least one major broker shifting to a less constructive stance and trimming assumptions around growth and valuation multiples.
LONN
CHF 504.20
Lonza Group
7D
-6.0%
1Y
-10.8%
XLS
CHF 22.10
Xlife Sciences
7D
-1.8%
1Y
6.3%